Miren Taberna

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 174 citations · Full text

Concurrent Chemoradiotherapy, Neoadjuvant Therapy, Squamous Cell Carcinoma +6

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Robert I. Haddad, Kevin J. Harrington, Makoto Tahara et al. · Journal of Clinical Oncology · 2022 · 142 citations · Full text

SEOM clinical guidelines for the treatment of head and neck cancer (2020)

L. Iglesias, J. Lambea, Javier Martínez‐Trufero et al. · Clinical & Translational Oncology · 2021 · 98 citations · Full text

Double positivity for HPV-DNA/p16ink4a is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients

M. Mena, Miren Taberna, Sara Tous et al. · Oral Oncology · 2018 · 79 citations · Full text

Human Papillomavirus Vaccines, Strongest Diagnostic Accuracy, Double Positivity +12